BofA downgrades Addus HomeCare stock rating on slowing growth

BofA Securities downgraded Addus HomeCare to Neutral from Buy and cut its price target to $125 from $140, reducing its EBITDA forecast and valuation multiple to 11x 2027E EBITDA from 12x. The downgrade reflects slowing organic growth and an expected worsening in state Medicaid budgets by fiscal 2028 as cuts from the 2025 reconciliation bill accumulate. Addus beat Q2 2026 expectations with adjusted EPS of $1.73 versus $1.69 consensus and revenue of $377.4 million versus $376.2 million, but shares declined as the beat was limited and segment trends were mixed.

Analysis

The relevant debate is not the next-quarter beat but whether Addus can offset a progressively less favorable Medicaid reimbursement pool through mix, scale, and acquisitions. Labor-intensive personal-care businesses have limited ability to absorb rate pressure: if state reimbursement grows below wage inflation, EBITDA margins can compress even while census and revenue continue to grow. This makes a lower terminal multiple more consequential than a modest reduction in near-term estimates, particularly for a stock whose historical premium depends on durable organic growth.

A Democratic-election premium is a weak near-term trading support rather than an investable earnings solution; state budget implementation and managed-care rate negotiations will determine economics on a 12-24 month horizon. Consolidation could be accretive only if acquired agencies have better local reimbursement rates or if Addus can eliminate meaningful overhead; paying up for assets ahead of known funding pressure would instead raise leverage and integration risk. Potential relative beneficiaries are larger diversified home-health operators such as HUM and CVS, which have more ability to influence or diversify reimbursement exposure, though their exposures are not directly comparable.

Consensus may be underestimating the timing mismatch: reimbursement cuts generally lag statutory changes, allowing reported results to remain resilient before margin pressure becomes visible in guidance. Conversely, bearish positioning could be premature if wage inflation eases and state rate updates remain constructive through fiscal 2027. The thesis is falsified by sustained organic revenue growth with stable or expanding adjusted EBITDA margin, or by disclosed rate actions that demonstrably cover wage and benefit inflation.

Key Decisions for Investors

• Maintain an underweight/watch stance on ADUS rather than chase any election-driven bounce over the next 1-3 months; require evidence that organic growth reaccelerates without EBITDA-margin erosion before upgrading the view.
• For portfolios requiring healthcare exposure, consider a 6-12 month relative-value position short ADUS versus long HUM or CVS only after confirming comparable beta and sizing for idiosyncratic M&A risk. The catalyst is fiscal-2028 state-budget and rate-setting commentary; exit if ADUS guides to stable margins alongside accelerating organic growth.
• Set an event alert around the next earnings release for three items: organic-growth rate, wage-cost growth versus reimbursement, and acquisition valuation/leverage. A material acquisition financed at an elevated multiple would strengthen the short case; rate relief sufficient to preserve margins would negate it.
• Avoid treating third-party fair-value or PEG screens as a catalyst. The key valuation input is the sustainable post-reimbursement EBITDA margin and terminal multiple, neither of which is resolved by a small revenue or EPS beat.